News | PET Imaging | January 25, 2017

Researchers use radiotracer that binds to mature olfactory sensory neurons to quantify neuronal populations

January 25, 2017 — In work published this week in the Journal of Clinical Investigation (JCI), a team led by Jacob Hooker at Harvard Medical School assessed GV1-57, a radiotracer that specifically binds to mature olfactory sensory neurons, as an approach for quantifying neuronal populations with positron emission tomography (PET) imaging.

Olfactory neurons in the nasal cavity are the primary source of our sense of smell. Unlike many types of neurons, olfactory neurons are continuously generated throughout the adult lifespan. This uniquely high rate of neuronal birth and death makes olfactory neurons particularly sensitive to the detrimental effects of progressive neurodevelopmental and neurodegenerative disease. In Alzheimer's disease and Parkinson's disease, loss of the sense of smell often precedes classical symptoms of cognitive or motor dysfunction. Therefore, a technique that is able to non-invasively quantify the olfactory neuron population could provide important insights related to the diagnosis and progression of neurodevelopmental and neurodegenerative diseases.

Using GV1-57, researchers were able to detect neuron generation during rodent postnatal development as well as neuron degeneration in rodent models of aging and neurodegenerative disease. In an additional proof-of-concept experiment, they showed that GV1-57 maintained saturable binding in non-human primate nasal cavity, suggesting that this radiotracer may be useful for evaluating neurological disease in clinical settings.

For more information: www.jci.org

Van de Bittner, G.C., Riley, M.M., Cao, L., Ehses, J., et al. "Nasal neuron PET imaging quantifies neuron generation and degeneration," The Journal of Clinical Invesigation. Published Jan. 23, 2017. doi:10.1172/JCI89162


Related Content

News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | ARRS

Feb. 11, 2026 —The American Roentgen Ray Society (ARRS) has announced the following radiologists, as well as their ...

Time February 13, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 6, 2026 — A state-of-the-art intraoperative MRI (iMRI) has arrived at the University of Chicago Medicine, one of ...

Time February 06, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Radiation Oncology

Jan. 8, 2026 — RefleXion Medical, an external-beam theranostic oncology company, has announced the U.S. Food and Drug ...

Time January 13, 2026
arrow
News | Radiopharmaceuticals and Tracers

Nov. 18, 2025 — Siemens Healthineers positron emission tomography (PET) radiopharmaceutical companies PETNET Solutions ...

Time November 18, 2025
arrow
News | Radiopharmaceuticals and Tracers

Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...

Time November 12, 2025
arrow
News | PET Imaging

Oct. 22, 2025 — Vistim Labs has announced that its flagship product, Ceregram, is officially ready for launch in ...

Time October 22, 2025
arrow
Subscribe Now